Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

nebivolol

  • You have access
    Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors
    YU JIN KIM, SE-KYEONG JANG, GYEONGMI KIM, SUNG-EUN HONG, CHAN SUB PARK, MIN-KI SEONG, HYUN-AH KIM, KWANG SEOK KIM, CHUN-HO KIM, KI SOO PARK, JUNGIL HONG, HYEON-OK JIN and IN-CHUL PARK
    Anticancer Research May 2023, 43 (5) 1973-1980; DOI: https://doi.org/10.21873/anticanres.16357
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire